Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

BOND-003 : A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Urinary System<br/>CancersCancer LocationUrinary System
Cancers

Systemic therapy | Urinary systemBladder

Trial Overview Read MoreRead more

This phase III trial is evaluating how effective administering immunotherapy (CG0070) through a tube directly into the bladder is to treat non-muscular invasive bladder cancer who have had previous immunotherapy (BCG).
 

This trial is treating patients with bladder cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

Commercial Sponsor

CG Oncology, Inc.

Summary

This is a single arm study for people with non-muscular invasive bladder cancer with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease, who have been unresponsive to prior BCG therapy. All participants will receive the same treatment. CG0070 will be administered intravesically (via urethral catheter) following a sequence of bladder washes with 5% DDM (n-dodecyl-B-D-maltoside Transduction-enhancing agent) and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the participant has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response), then the participant will receive 3 weekly treatments. Beginning at Week 25, participants will receive weekly x3 treatments every 12 weeks through week 49, then every 24 weeks thereafter.

Recruiting Hospitals Read MoreRead more

Barwon Health, University Hospital Geelong
Geelong
Oncology Team
OncologyTrials@barwonhealth.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next